Drug-induced renal failure in the ICU

International Journal of Artificial Organs

Volumn 27, Issue 12, 2004, Pages 1034-1042

  Joannidis, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

ACE inhibitors; Aminoglycosides; Amphotericin B; Antiviral drugs; Calcineurin inhibitors; Intravenous immune globulin; NSAIDs; Sulfadiazine

Indexed keywords

ACE INHIBITORS; AMINOGLYCOSIDES; AMPHOTERICIN B; ANTI-VIRAL DRUGS; CALCINEURIN INHIBITORS; HYPOVOLEMIA; INTRAVENOUS IMMUNE GLOBULIN; NSAID; RENAL FAILURE; SULFADIAZINE;

ACICLOVIR; ADEFOVIR; ALLOPURINOL; AMINOGLYCOSIDE; AMPHOTERICIN B; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN; CIDOFOVIR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; HETASTARCH; IMMUNOGLOBULIN; INDINAVIR; LITHIUM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; RANITIDINE; RAPAMYCIN; RIFAMPICIN; SUCROSE; SULFADIAZINE; SULFONAMIDE; TACROLIMUS; UNINDEXED DRUG; VANCOMYCIN;

AGING; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; FREQUENCY ANALYSIS; HEMODYNAMIC PARAMETERS; HUMAN; HYPOVOLEMIA; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY EPITHELIUM; KIDNEY FAILURE; NEPHRITIS; REVIEW; RISK ASSESSMENT;

EID: 12444288056     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. Semin Nephrol 1997; 17: 3-14.
2. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288: 2547-53.
3. Hooi LS. Acute renal failure requiring dialysis-a 5 year series. Med J Malaysia 1997; 52: 251-6.
4. Jochimsen F, Schafer JH, Maurer A, Distler A. Impairment of renal function in medical intensive care: Predictability of acute renal failure. Crit Care Med 1990; 18: 480-5.
5. Kraman S, Khan F, Patel S, Seriff N. Renal failure in the respiratory intensive care unit. Crit Care Med 1979; 7: 263-6.
6. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24: 192-8.
7. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643-53.
8. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: Evaluation of selective and non-selective cyclooxygenase inhibitors. J Intern Med 2003; 253: 643-52.
9. Lee A, Cooper MC, Craig JC, Knight JF, Keneally JP. Effects of nonsteroidal anti-inflammatory drugs on post-operative renal function in normal adults. Cochrane Database Syst Rev 2001; CD002765.
10. Dzeka TN, Townley R, Arnold JM. Effects of enalaprilat on venoconstriction to norepinephrine: Role of prostaglandins. Cardiovasc Res 2003; 59: 250-6.
11. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 111: 64-7.
12. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84.
13. FDA Arthritis Advisory Committee. Celebrex: Briefing Document: Renal Effects. 1998 Available at: http://www.fda.gov/cder/foi/adcomm/98/celebrex.htm
14. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999; 10 (suppl 12): S266-72.
15. Bennett WM. Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Ren Fail 1996; 18: 453-60.
16. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, Barrett A, Jameson B, Depledge MH, Watson JG, Sloane J, Leigh M, Lumley H, Hedley D, Lawler SD, Filshie J, Robinson B. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612-5.
17. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002; 359: 741-6.
18. Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, Hauser I, Wagner K, Neumayer HH: Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial. Lancet 1999; 354: 1415-20.
19. Palmer BF, Dawidson I, Sagalowsky A, Sandor Z, Lu CY. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52: 640-5.
20. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-11.
21. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001; 357: 587-91.
22. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-17.
23. Bertino JS, Jr., Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173-9.
24. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, Shusterman NH, Strom BL. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900-9.
25. Baciewicz AM, Sokos DR, Cowan RI. Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother 2003; 37: 182-6.
26. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13: 735-9.
27. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55.
28. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Am J Health Syst Pharm 1996; 53: 1141-50.
29. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7.
30. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989; 87: 547-52.
31. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Platt R: Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001; 60: 1452-9.
32. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: A review. J Chemother 2000; 12: 463-70.
33. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528-34.
34. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2389-4.
35. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 2001; 322: 579-82.
36. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
37. Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 339-44.
38. Meier P, Dautheville-Guibal S, Ronco PM, Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17: 148-9.
39. Cundy KC, Barditch-Crovo, P, Walker RE, Collier AC, Ebeling D, Toole J, Jaffe HS. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1995; 39: 2401-5.
40. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11: 383-93.
41. Safrin S, Cherrington J, Jaffe HS. Cidofovir. Review of currert and potential clinical uses. Adv Exp Med Biol 1999; 458: 111-20.
42. Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, Rozenheim M, Baumelou A, Dohin E, Gentilini M. Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am J Nephrol 1989; 9: 316-21.
43. Beaufils H, Deray G, Katlama C, Dohin E, Henin D, Sazdovitch V, Jouanneau C. Foscarnet and crystals in glomerular capillary lumens. Lancet 1990; 336: 755.
44. Cacoub P, Deray G, Baumelou A, Le Hoang P, Rozenbaum W, Gentilini M, Soubrie C, Rousselie R, Jacobs C. Acute renal failure induced by foscarnet: 4 cases. Clin Nephrol 1988; 29: 315-8.
45. Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity. Ann Intern Med 1990; 113: 332.
46. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987; 82: 624-9.
47. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-34.
48. Sati HI, Ahya R, Watson HG. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001; 113: 556-7.
49. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: A report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8: 1788-94.
50. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 248-9.
51. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620-2.
52. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001; 357: 911-6.
53. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cadiac surgery: Comparison of a new starch preparation with gelatin. Intensive Care Med 2003; 29: 763-9.
54. Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G. Volume therapy in the critically ill: Is there a difference? Intensive Care Med 1998; 24: 28-36.
55. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35: 1257-70.
56. Kleinknecht D, Landais P, Goldfarb B. Acute renal failure associated with drugs or iodinated contrast media. Results of a cooperative multicentric study by the Nephrology Society. Nephrologie 1986; 7: 41-6.
57. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126-9.
58. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf 2001; 24: 491-501.
59. Dzik WH, Georgi BA, Khettry U, Jenkins RL. Cyclosporine-associated thrombotic thrombocytopenic purpura following liver transplantation-successful treatment with plasma exchange. Transplantation 1987; 44: 570-2.
60. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8: 286-93.
61. Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail 1998; 20: 809-19.
62. Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982; 73: 182-5.
63. Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985; 151: 362-5.
64. Gnann JW, Jr., Barton NH, Whitley RJ. Acyclovir: Mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy 1983; 3: 275-83.
65. Keeney RE, Kirk LE, Bridgen D. Acyclovir tolerance in humans. Am J Med 1982; 73: 176-81.
66. Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988; 84: 1067-71.
67. Vomiero G, Carpenter B, Robb I, Filler G. Combination of ceftriaxone and acyclovir - an underestimated nephrotoxic potential? Pediatr Nephrol 2002; 17: 633-7.
68. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, Pannell LK, Falloon J. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-25.
69. Berns JS, Cohen RM, Silverman M, Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases. Am J Kidney Dis 1997; 30: 558-60.
70. Simon DI, Brosius FC, III, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 1990; 150: 2379-84.
71. de Sequera P, Albalate M, Hernandez J, Vazquez A, Abad J, Ramiro E, Fernandez GM, Caramelo C, Casado S, Ortiz A. Acute renal failure due to sulphadiazine crystalluria in AIDS patients. Postgrad Med J 1996; 72: 557-8.
72. Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 1988; 12: 72-5.